Sanofi (NASDAQ:SNY) Receives Average Recommendation of "Buy" from Brokerages

Shares of Sanofi (NASDAQ:SNY - Get Free Report) have received an average recommendation of "Buy" from the five research firms that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $62.50.

SNY has been the subject of a number of research reports. Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. The Goldman Sachs Group started coverage on shares of Sanofi in a research report on Friday. They set a "neutral" rating and a $65.00 price objective for the company. StockNews.com downgraded shares of Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its stake in shares of Sanofi by 31.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company's stock worth $8,040,000 after purchasing an additional 33,105 shares during the period. Arkadios Wealth Advisors boosted its position in shares of Sanofi by 19.0% during the fourth quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company's stock valued at $227,000 after buying an additional 751 shares during the period. Geode Capital Management LLC grew its stake in shares of Sanofi by 7.1% during the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company's stock valued at $14,681,000 after buying an additional 16,780 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Sanofi by 20.9% in the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company's stock worth $133,172,000 after buying an additional 399,301 shares during the period. Finally, Icon Wealth Advisors LLC raised its holdings in shares of Sanofi by 7,954.4% in the third quarter. Icon Wealth Advisors LLC now owns 292,779 shares of the company's stock worth $16,873,000 after buying an additional 289,144 shares during the period. Institutional investors own 14.04% of the company's stock.

Remove Ads

Sanofi Price Performance

SNY traded down $0.94 during trading on Friday, hitting $55.96. 687,873 shares of the company traded hands, compared to its average volume of 2,264,797. The company has a market cap of $142.02 billion, a PE ratio of 22.47, a P/E/G ratio of 1.01 and a beta of 0.58. Sanofi has a 1 year low of $45.22 and a 1 year high of $60.12. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The stock's 50-day simple moving average is $54.55 and its two-hundred day simple moving average is $52.85.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, sell-side analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.